Patents by Inventor Lloyd J. Old
Lloyd J. Old has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117073Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: April 26, 2023Publication date: April 11, 2024Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard C. Nice, Anne Murray, George Mark
-
Publication number: 20210032366Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: March 13, 2020Publication date: February 4, 2021Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
-
Patent number: 10385138Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: May 31, 2017Date of Patent: August 20, 2019Assignees: Ludwig Institute for Cancer Research Ltd., Sloan-Kettering Cancer Institute, Institute of Molecular Biology and Genetics National Academy of Science of UkraineInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Publication number: 20180057606Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: July 27, 2017Publication date: March 1, 2018Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
-
Publication number: 20170362336Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: ApplicationFiled: May 31, 2017Publication date: December 21, 2017Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 9701755Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: April 22, 2015Date of Patent: July 11, 2017Assignees: Ludwig Institute for Cancer Reserach Ltd., Sloan Kettering Cancer Institute, Institute of Molecular Biology and Genetics National Academy of Science of UkraineInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 9562102Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: GrantFiled: December 11, 2012Date of Patent: February 7, 2017Assignee: Ludwig Institute for Cancer ResearchInventors: Lloyd J. Old, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Webster K. Cavenee
-
Patent number: 9283276Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: August 14, 2008Date of Patent: March 15, 2016Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephen Stockert, Lloyd J. Old, Andrew M. Scott, Veronika M. Rayzman
-
Publication number: 20160046726Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: June 11, 2015Publication date: February 18, 2016Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
-
Patent number: 9260524Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: GrantFiled: December 11, 2012Date of Patent: February 16, 2016Assignee: Ludwig Institute for Cancer ResearchInventors: Lloyd J. Old, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Webster K. Cavenee
-
Publication number: 20160009816Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: ApplicationFiled: April 22, 2015Publication date: January 14, 2016Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 9045533Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: September 26, 2013Date of Patent: June 2, 2015Assignees: Ludwig Institute for Cancer Research Ltd, Institute for Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan Kettering Cancer InstituteInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Publication number: 20140255436Abstract: The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide.Type: ApplicationFiled: April 7, 2014Publication date: September 11, 2014Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCHInventors: Takemasa TSUJI, Sacha Gnjatic, Gerd Ritter, Lloyd J. Old
-
Publication number: 20140255410Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: September 11, 2014Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20140193417Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: ApplicationFiled: September 26, 2013Publication date: July 10, 2014Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 8652473Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.Type: GrantFiled: January 29, 2010Date of Patent: February 18, 2014Assignees: Ludwig Institute for Cancer Research Ltd., Massachusetts Institute for Technology, Commonwealth Scientific and Industrial Research OrganizationInventors: Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
-
Publication number: 20130266573Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: October 10, 2013Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Patent number: 8541202Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.Type: GrantFiled: February 24, 2012Date of Patent: September 24, 2013Assignee: Ludwig Institute for Cancer ResearchInventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
-
Patent number: 8357373Abstract: The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system.Type: GrantFiled: October 3, 2006Date of Patent: January 22, 2013Assignees: Ludwig Institute for Cancer Research, Yale UniversityInventors: Lloyd J. Old, Gerd Ritter, Hiroyoshi Nishikawa, Sacha Gnjatic, Jorge E. Galan
-
Publication number: 20120328660Abstract: The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide.Type: ApplicationFiled: May 31, 2012Publication date: December 27, 2012Inventors: Takemasa TSUJI, Sacha Gnjatic, Gerd Ritter, Lloyd J. Old